123 results about "Clinical screening" patented technology

Embodiments of the invention provide methods, assays, and kits for detecting HPV infection, including infection by various HPV genotypes, early and/or late HPV-associated or HPV-specific proteins or antibodies. Detection of HPV DNAs, genomes, and/or oncoproteins by protein chips immunological assays can be used in early clinical screening for HPV infection and general diagnosis for cervical cancer and can be advantageous performed in a multiplexed test. Comparative detection of altered levels of HPV proteins and host proteins can performed in one or more assays. The polypeptides, recombinant proteins, antibodies, nucleic acids, and various detection methods thereof are particularly useful for diagnosing carcinomas of the uterine cervix and those at risk of developing cervical cancer.

The invention discloses a deep learning-based diabetic retina image classification method and system in the technical field of artificial intelligence. The method comprises steps: a fundus image is acquired; the same fundus image is imported to a microvascular tumor-like lesion recognition model, a hemorrhagic lesion recognition model and an exudative lesion recognition model for recognition; andaccording to recognition results, lesion feature information is extracted, a trained SVM classifier is then adopted to classify the extracted lesion feature information, and a classification result isacquired, wherein the microvascular tumor-like lesion recognition model is obtained when a microvascular tumor-like lesion candidate area in the fundus image is extracted and is then inputted to a CNN model for training, and the hemorrhagic lesion recognition model and the exudative lesion recognition model are obtained when a hemorrhagic lesion area and an exudative lesion area in the fundus image are marked and are then inputted to an FCN model for training. The requirements on the description ability of the network model are reduced, the model is easy to train, a lesion focus area is positioned and delineated for different lesions, and clinical screening by a doctor is facilitated.

The present invention concerns genes containing mutations associated with autism its onset and development and also to the encoded proteins of said genes associated with autism, its onset and development and the use of said genes, proteins or protein isoforms. The invention thus also relates to methods of screening for, diagnosis and treatment of autism in human subjects e.g., clinical screening, diagnosis, prognosis, therapy and prophylaxis, as will as for drug screening and drug development.

An embodiment of the present invention uses logistic regression models that correlate post-marketing ADRs with screening data from the PubChem BioAssay database. These models of the present invention analyze ADRs at the level of organ systems, the System Organ Classes (SOCs). In testing to evaluate an embodiment of the present invention, nine of 19 SOCs under consideration were found to be significantly correlated with pre-clinical screening data. For six of eight established drugs for which SOC-specific adversities could be retropredicted, prior knowledge was found that support these predictions. SOC-specific adversities were then predicted for three unapproved or recently introduced drugs.

Embodiments of the invention provide methods, assays, and kits for detecting HPV infection and HPV associated epithelial cell abnormalities, most notably those associated with pre-malignant and malignant epithelial cell lesions. Detection of HPV DNAs, genomes, and/or oncoproteins by nucleic acid hybridization assays and immunological assays can be used in early clinical screening for HPV infection and diagnosis for cervical cancer. The polypeptides, recombinant proteins, antibodies, nucleic acids, and various detection methods thereof are particularly useful for diagnosing carcinomas of the uterine cervix and those at risk of developing cervical cancer.

The invention discloses a traditional Chinese medicine preparation for treating cervical vertigo, which is mainly prepared by combining the following 18 traditional Chinese medicines according to certain weight proportions: tuber pinellia, bighead atractylodes rhizome, gastrodia tuber, tuckahoe, dried orange peel, peach kernel, safflower, angelica, prepared rhizome of rehmannia, red peony root, hemlock parsley, hawthorn, bamboo shavings, grass-leaved sweetflag, baikal skullcap root, selfheal spike, kudzu root and licorice. Aiming at the pathogenesis that cervical vertigo always happens along with endopathic wind, phlegm, deficiency, blood stasis and the like, the cervical vertigo needs to be treated on both principal and secondary aspects of disease. Through clinical screening and comparative observation, the comprehensive treatment principles of calming the endopathic wind and removing heat, eliminating dampness and eliminating phlegm, restoring qi and nourishing the blood, and promoting blood circulation and removing blood stasis are organically combined, and through observation on multiple indices of clinical symptoms, physical signs, TCD, BAEP, haemorheology, and the like, the total effective rate of the treatment group is 96.7%, and the effects on improving the TCD, BAEP and haemorheology of the treatment group are obviously superior to the effects of the control group. Thus, the method has exact and obvious treatment effect on the cervical vertigo. The preparation for treating cervical vertigo is a pure traditional Chinese medicine preparation, is convenient to take and has no toxic and side effects.

The invention belongs to the technical field of medical devices, and particularly relates to an emergency internal medicine clinical examination device. The scheme is put forward at present for solving the problems that medicines and examination instruments are not convenient to carry during clinical examination and meanwhile the temperature difference easily causes discomfort to a patient when the examination instruments act on a human body. The clinical examination device comprises a box body. Round through holes are formed in the four corners of the bottom of the box body respectively. Eachround through hole is internally connected with a supporting device through a bolt. The inner wall of the bottom of the box body is connected with an instrument fixing frame through bolts. The surface of the instrument fixing frame is wrapped by a memory sponge cover. By means of an ultrasonic modulator tube, the examination instruments in a tool storage box and the instruction fixing frame can be regularly disinfected and sterilized, and the safety of the examination instruments is kept; a heating plate can directly act on and heat the human body examination instruments, and it is avoided that the examination instruments cause discomfort to the patient due to the cold temperature during examnation.

The invention provides a detection kit to judge whether solid tumors are suited for immunotherapy. The detection kit includes detection reagents for detecting the indexes: tumor mutation load of peripheral blood circulating tumor DNA, HLA typing, HLA state of loss of heterozygosity, PD-L1 membrane expression positive tumor cell percentage, infiltration level of CD8+ immune cells, infiltration level of FOXP3+ immune cells, mRNA expression score of T-cell inflammation related genes, percentage of CD14+CD16-HLA-DR+ monocytes in peripheral blood mononuclear cells, and micro-satellite instability.The invention also provides, correspondingly, a method to judge whether solid tumors are suited for immunotherapy. The kit and method herein can be used to screen patients with solid tumors so as to provide significantly increased objective response rate and have a promising application prospect in terms of clinical screening of patients with solid tumors suited for immunotherapy.

The invention discloses a method for detecting ureaplasma urealyticum and tiny urealyticum, which belongs to the technical field of detection of microporous plates. The method for detecting ureaplasma urealyticum and tiny urealyticum has the characteristics that clinical samples processed by thermal denaturation after PCR (polymerase chain reaction) amplification are respectively added to micro holes of a DNA-BINDING96 hole determination plate equipped coated with Uu and Up specific probes, and positive control holes are arranged, to which Uu and Up serotype standard strains processed by thermal denaturation after PCR amplification are added; after thermostat hybridization, the plate is cleaned and is patted to be dry; streptavidin-horseradish peroxidase conjugates are added to each hole, the plate is cleaned, and the streptavidin-horseradish peroxidase conjugates are dried in air; then, chromogenic substrates A and B are added to each hole, and color development is performed in a shady place after the mixture becomes homogeneous; finally, a stop solution is added, and the result is determined according to color change. The method for detecting ureaplasma urealyticum and tiny urealyticum not only solves the problem of false positive result caused by determining a positive result according to color change of a liquid medium, but also can accurately identify Uu and Up, thereby improving the detection sensitivity. Moreover, high-flux detection is realized, and the method for detecting ureaplasma urealyticum and tiny urealyticum can be widely used for clinical screening.

The invention discloses an application of miR-15a as a molecular marker for clinical screening of aortic dissection, wherein the sequence of miR-15a is showed as the SEQ ID NO.1. A kit for clinical screening of aortic dissection is characterized by comprising: a blood plasma general RNA extraction reagent group, an exogenous reference object, a RNA reverse transcription reagent group, a RNA reverse transcription primer group, a realtime quantitative PCR reagent group, a realtime quantitative PCR primer group and a realtime quantitative PCR probe group, wherein the RNA reverse transcription primer group comprises a miR-15a reverse transcription primer and an exogenous reference object reverse transcription primer, the realtime quantitative PCR primer group comprises a miR-15a realtime quantitative PCR primer and an exogenous reference object realtime quantitative PCR primer, and the realtime quantitative PCR probe group comprises a miR-15a realtime quantitative PCR probe and an exogenous reference object realtime quantitative PCR probe.

The invention discloses an SNP (single nucleotide polymorphism) parting chip, a detection reagent and a kit for the detection of NLRP 7 gene related to hydatid mole, which builds a gene chip detection system for screening NLRP7 gene polymorphism high risk groups related to hydatid mole. The gene chip comprises a solid phase carrier and an oligonucleotide probe synthetized on the carrier, the detection reagent comprises a gene chip and 18 pairs of PCR (polymerase chain reaction) primers for amplifying all SNPs in a sample, and the kit comprises the detection reagent, a negative check sample and a positive check sample. The chip, the detection reagent and the kit can be used for detecting all SNPs locus related to the NLRP7 gene in the clinical sample rapidly and accurately. The detection system has large flux and high sensitivity, has significance for clinical diagnosis of hydatid mole as well as early screening and early prevention of high risk groups, and can be widely used in effective clinical screening of the hydatid mole high risk groups.

The present invention relates to a biomarker for Parkinson's disease. The biomarker and products associated with the biomarker may be used to assist diagnosis or to assess onset and/or development of Parkinson's disease. The invention also relates to use of the biomarker in clinical screening, assessment of prognosis, evaluation of drug treatments, drug screening or drug development in the field of Parkinson's disease and Parkinson's disease related disorders.

The invention discloses an amide compound and an application thereof in treating cancer, and belongs to the field of pharmaceutical chemistry. The invention discloses the application of amide compoundshown in formula I, or crystal form, or stereoisomer, or isotope body, or tautomer, or pharmaceutically-acceptable salt, or solvate, or pro-drug, or metabolite thereof in treating cancer. Experimental results show that the compound can inhibit the proliferation of prostate cancer cells, especially has an obvious inhibition effect on drug-resistant prostate cancer cell line (22RV1). At the same time, the compound can obviously inhibit the proliferation of multiple cancer cells. In addition, the compound has good pharmacokinetics, which has a potential therapeutic effect on cancer, especially prostate cancer, and provides a new choice for clinical screening and/or preparation of cancer drugs.

The invention provides a detection kit for c.403>T mutation of the CDH23 gene. Causes and types of hereditary hearing loss and/or Usher ID syndrome are diagnosed through detecting whether patients have the mutation gene or not. The mutation gene and a detection method mentioned above are beneficial for clinical screening of CDH23 mutation for patients with hereditary hearing loss, providing bases for diagnosis and treatment of patients with hereditary hearing loss and Usher ID syndrome.

The invention discloses scar-removing silica gel and a preparation method thereof. The scar-removing silica gel is prepared from the following raw materials in percentage by weight: 1-5% of asiaticoside, 1-5% of laminarin, 1-5% of paeonol, 5-15% of safflower seed oil, 15-20% of polydimethylsiloxane, 3-5% of one or more emulsifiers, 41-60% of water and 5-15% of glycerin. Through the adoption of the scar-removing silica gel, the gel sensitization rate is low, and a safer and more effective scar-removing method is provided for patients; long-term research and clinical screening show that the scare-removing effect is remarkable and the cure rate is high; the scar-removing silica gel is an efficient scar-removing preparation for external use and combines traditional Chinese medicine theories of promoting blood circulation to remove blood stasis, softening hard mass and removing stagnation, and regenerating tissues and relieving itching with the conventional technology; the preparation method is simple in technology and low in cost.

The invention discloses an accelerator capable of improving a functionalization process of adoptive DCs (Dendritic Cells), as well as a preparation method and application of the accelerator. Main ingredients of the accelerator comprise an immunologic stimulant-nanometer gold compound and an antigen-nanometer gold compound, which are obtained by modifying gold nanoparticles with an immunologic stimulant and an antigen respectively; or the main ingredients comprise an immunologic stimulant-antigen-nanometer gold compound obtained by jointly modifying the gold nanoparticles with the immunologic stimulant and the antigen. According to the accelerator, nanometer gold with the characteristics of high biocompatibility, adjustable surface physicochemical properties and the like is used as a nanometer targeting vector of adoptive DCs vaccines, and the shapes or the particle sizes of the nanometer material are screened or effectively combined for properties of different junctional complexes, so that the homing efficiency of lymphoid organs under the local or intravenous infusion of the adoptive DCs vaccines is greatly improved, and a new idea is provided for clinical screening in the future.

The present invention relates to novel antibodies, antibody fragments and antibody conjugates which display a high degree of selectivity for squamous cell carcinoma antigens including carcinomas of the lung, esophagus and cervix. The present invention relates to both in vivo and in vitro clinical screening methods for diagnosis or prognosis of carcinomas by means of detecting the expression of squamous cell carcinoma antigens in biological samples of the subject using the novel antibodies of the invention. The invention further provides for kits for carrying out the above described screening methods. Additionally, antibody conjugates may be used to efficiently deliver various agents which have anti-tumor effects to the tumor cell. The antibodies of the invention may also be administered to a patient in non-conjugated form to target ADCC to the tumor cell.

The invention discloses an automatic clinical service database building method based on Excel import, and the method comprises the steps: automatically creating a clinical trial research service and automatically importing clinical data of a subject according to the contents and format of a large amount of Excel clinical stock data, including: creating subject group information, creating a clinical screening stage and clinical data collection stage, designing an electronic CRF that is matched with the Excel data format at each stage, automatically importing the clinical data of the Excel subject into the established clinical trial research service, realizing the automatic creating of the clinical service based on Excel import, and achieving the collection of new subject data based on the clinical trial research created based on the Excel import. By adopting the technical scheme of the invention, the design process conforming to the clinical trial specification can save the time of clinical design, shorten the cycle of clinical research, improve the efficiency of clinical trial research design and clinical data collection, and facilitate the management and analysis of Excel stock data by clinical researchers.

The invention discloses a compound shown as formula I in the specification, or a stereoisomer, or a pharmaceutically acceptable salt, or a solvate, or a prodrug, or a metabolite, or a deuterated derivative thereof. Belonging to the field of pharmaceutical chemistry, the compound is a polysubstituted triazole formate derivative with a novel structure. The invention also discloses application of thepolysubstituted triazole formate derivative in preparation of drugs with sedative, hypnotic and/or anesthetic effects, and application in preparation of drugs capable of controlling status epilepticus. The compound has good inhibition effect on the central nervous system, and provides a new choice for clinical screening and/or preparation of drugs with sedative, hypnotic and/or anesthetic effectsand status epilepticus controlling function.